Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 411
- Registration Number
- NCT01375777
- Locations
- 🇩🇰
Research Site, Vejle, Denmark
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 328
- Registration Number
- NCT01370603
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 406
- Registration Number
- NCT01370590
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 200
- Registration Number
- NCT01236430
Effect of Simvastatin and Ezetimibe on Lipid and Inflammation
- Conditions
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 50
- Registration Number
- NCT01103648
- Locations
- 🇧🇷
Hospital do Rim e Hipertensao da UNIFESP, Sao Paulo, Brazil
The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome
- Conditions
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Yokohama City University Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT01068093
- Locations
- 🇯🇵
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 39
- Registration Number
- NCT01035320
- Locations
- 🇸🇪
Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), Stockholm, Sweden
Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2009-11-06
- Lead Sponsor
- Hotel Dieu de France Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01008345
- Locations
- 🇱🇧
Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
- Conditions
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT00988364
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2009-09-10
- Lead Sponsor
- Bronx VA Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00972829
- Locations
- 🇺🇸
Bronx VA Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.